Abstract
Functional PET (fPET) is a novel technique for studying dynamic changes in brain metabolism and neurotransmitter signaling. Accurate measurement of the arterial input function (AIF) is crucial for quantification of fPET but traditionally requires invasive arterial blood sampling. While, image-derived input functions (IDIF) offer a non-invasive alternative, they are afflicted by drawbacks stemming from limited spatial resolution and field of view. Therefore, we conceptualized and validated a scan protocol for brain fPET quantified with cardiac IDIF.
Twenty healthy individuals underwent fPET/MR scans using [18F]FDG or 6-[18F]FDOPA, with bed motion shuttling between the thorax and brain to capture cardiac IDIF and brain task- induced changes, respectively. Each session included arterial and venous blood sampling for IDIF validation, and participants performed a monetary incentive delay task. IDIFs from fixed- size regions of the left ventricle, ascending and descending aorta, and a composite of all 3 blood pools (3VOI) plus venous blood data (3VOIVB) were compared to the AIF. Quantitative task-specific images from both tracers were compared to assess the performance of each input function.
For both radiotracer cohorts, moderate to high agreement was found between IDIFs and AIF in terms of area under the curve (r = 0.64 – 0.89) and quantified outcome parameters (CMRGlu and Ki(r)=0.84–0.99). The agreement further increased for composite IDIFs 3VOI and 3VOIVB for AUC(r)=0.87–0.93) and outcome parameters (r=0.96–0.99). Both methods showed equivalent quantitative values and high spatial overlap with AIF-derived measurements.
Our proposed protocol enables accurate non-invasive estimation of the input function with full quantification of task-specific changes, addressing the limitations of IDIF for brain imaging by sampling larger blood pools over the thorax. These advancements increase applicability to virtually any PET scanner and to clinical research settings by reducing experimental complexity and increasing patient comfort.
Competing Interest Statement
With relevance to this work, there is no conflict of interest to declare. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers.
Funding Statement
This research was funded in whole, or in part, by the Austrian Science Fund (FWF) [KLI 1006, PI: R. Lanzenberger] and the WWTF Vienna Science and Technology Fund [CS18-039 Co-PI: Rupert Lanzenberger].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee (ethics numbers: 2259/2017 and 2321/2019) of the Medical University of Vienna and procedures were carried out in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
Raw data will not be publicly available due to reasons of data protection. Processed data and custom code can be obtained from the corresponding author with a data-sharing agreement, approved by the departments of legal affairs and data clearing of the Medical University of Vienna.
